CHM-2101

· Chimeric Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CHM-2101, covering 2026-01-29 to 2026-01-29. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy [Phase 1, Phase 2]

See pricing